ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 13, 2026 at 4:56 PM ET. Details in the imprint.

ResMed Inc. remains in focus for US investors in mid-2026 as the sleep and respiratory care specialist trades under noticeable year-to-date pressure, even as institutional investors continue to adjust their positions and the company comes off a better-than-expected earnings print earlier this year. According to Simply Wall St. data cited in recent coverage, the stock has lost around 21 percent of its value since the start of 2026, putting ResMed among the notable underperformers in its medical technology peer group. At the same time, market data compiled by MarketBeat show that the company delivered quarterly earnings per share of $2.86 on revenue of $1.43 billion in its most recently reported quarter, both ahead of consensus expectations and up 10.8 percent year over year, while the stock still carries a "Moderate Buy" consensus rating and an average analyst price target of $286.18. These mixed signals between share price performance and fundamental and analyst support frame the current debate around the Nasdaq-listed ResMed stock for US retail investors.

Institutional flows and analyst stance put ResMed under the microscope

Recent ownership disclosures highlight that institutional investors continue to see strategic value in ResMed despite the stock's weaker performance in 2026. Filings compiled by MarketBeat show that Milford Funds Ltd. has initiated a new position in ResMed shares valued at approximately $28.42 million, signaling fresh professional interest in the name. While the exact size of Milford's stake relative to total shares outstanding is not specified, the dollar amount is meaningful in the context of a single fund committing new capital to a stock that has been trending lower year to date. For US retail investors watching institutional money, such moves are often interpreted as a vote of confidence in the company's medium-term fundamentals even when the chart looks challenging in the short run.

Alongside these ownership updates, the sell-side analyst community continues to take a constructive, though not euphoric, view of ResMed's prospects. Consensus data compiled by MarketBeat indicate that the stock is currently rated "Moderate Buy," reflecting a mix of buy and hold recommendations and no broad-based capitulation by analysts following the company. The average price target of $286.18 per share stands notably above the levels where the stock has traded during its 2026 drawdown, implying that, on average, analysts still model upside based on their earnings and cash flow projections. That said, this aggregate target masks individual differences in conviction and risk assessment among covering firms, and targets are subject to revision as new financial and regulatory information emerges.

The analyst stance is grounded in ResMed's recent financial delivery, which has so far remained resilient despite sector headwinds and heightened competition in the broader medtech space. In its latest reported quarter, the company posted earnings per share of $2.86, exceeding consensus expectations of $2.79, and revenue of $1.43 billion, representing 10.8 percent year-over-year growth, according to MarketBeat's compilation of results. This combination of a modest earnings beat and double-digit top-line expansion reinforces the view that demand for ResMed's core sleep apnea and respiratory devices and related software platforms remains solid. The market's response, however, has been tempered, suggesting that investors are weighing these positives against concerns about valuation, reimbursement dynamics, and the long-term competitive landscape.

From a trading perspective, ResMed is listed on the New York Stock Exchange under the ticker symbol "RMD," giving US investors direct access in US dollars during regular US market hours. The stock is commonly grouped with larger US and global medical technology and health care equipment names, and while it is not part of the Dow Jones Industrial Average, it is followed as a component of broader health care and growth-focused indices where applicable. Internationally, the company also has a listing on the Australian Securities Exchange under the symbol "RMD.AX," which provides an additional liquidity pool for investors in Asia-Pacific time zones, although US retail investors typically focus on the US listing for better depth and tighter spreads. The dual-listing structure means that developments in one market can influence sentiment and arbitrage activity in the other, even if day-to-day price moves may differ because of currency and local investor flows.

The disconnect between ResMed's share price performance so far in 2026 and its underlying earnings momentum has drawn attention from both fundamental and quantitative investors. On the one hand, the 21 percent year-to-date decline highlighted by Simply Wall St. puts the stock into what many market participants would classify as a significant drawdown territory, especially for a profitable, established medtech company rather than a speculative early-stage biotech. On the other hand, the solid quarterly beat and double-digit revenue growth suggest that near-term operational execution has not materially faltered. This tension can create a more volatile trading environment as different investor cohorts recalibrate their models for growth, margins, and valuation multiples in light of changing macro conditions, such as interest rates and health care policy trends.

ResMed's revenue base is heavily tied to recurring demand for equipment and consumables in the sleep and respiratory care markets, areas that benefit from demographic tailwinds but can also be sensitive to changes in payer behavior and competitive pricing. The latest quarter's 10.8 percent year-over-year sales growth points to continued adoption of the company's devices and software solutions in key geographies, including North America, Europe, and Asia-Pacific. However, investors are also watching for any signs that growth may slow as post-pandemic normalization continues and as rivals innovate in adjacent product categories. Moreover, supply chain and cost inflation pressures that affected many medical equipment companies in recent years remain part of the broader risk discussion, even if ResMed has managed these factors reasonably well so far, as implied by its ability to beat EPS expectations.

Capital allocation and balance sheet strength are additional elements in how the market is assessing ResMed at this stage. The company's consistent profitability and cash generation provide it with flexibility to invest in research and development, pursue targeted acquisitions, and return capital to shareholders where appropriate. While the specific details of its latest capital return policies, such as dividends or share repurchase programs, are not outlined in the current data set, ResMed's track record in capital deployment is one reason why long-term institutional investors remain engaged. New stakes like that of Milford Funds Ltd. can therefore be seen against a backdrop of an established medtech name that continues to reinvest in its franchise while navigating valuation resets in the broader growth stock segment.

For US retail investors evaluating the stock, the combination of a notable year-to-date share price decline, solid recent earnings, and a sustained "Moderate Buy" analyst consensus underscores the importance of aligning any view on ResMed with individual risk tolerance and investment horizon. The stock offers exposure to structural themes such as aging populations and increased diagnosis of sleep-related disorders but also carries typical sector-specific risks, including regulatory shifts, product safety considerations, and technology disruption. Against this backdrop, investors watching the stock may want to pay close attention to upcoming quarterly reports, further ownership disclosures, and any updates from the company's investor relations channels, including its official website at ResMed, to gauge whether fundamental performance eventually reconciles with the stock's 2026 trading pattern.

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.